Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD0516 |
| Synonyms | |
| Therapy Description |
AZD0516 is an antibody-drug conjugate (ADC) comprising an antibody targeting STEAP2 linked to exatecan, which potentially induces cytotoxicity against STEAP2-expressing tumor cells and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1158). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD0516 | AZD-0516|AZD 0516 | AZD0516 is an antibody-drug conjugate (ADC) comprising an antibody targeting STEAP2 linked to exatecan, which potentially induces cytotoxicity against STEAP2-expressing tumor cells and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1158). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07181161 | Phase Ib/II | AZD0516 + AZD9574 AZD0516 | Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer (SEACLIFF) | Recruiting | USA | POL | ITA | GBR | FRA | ESP | BRA | 3 |